PointState Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

PointState Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-700,000	Closed	-$78.4M	–	138
2021 Q4	$78.4M	Buy	+700,000	New	+$84.4M	1.3%	25
2021 Q2	–	Sell	-50,000	Closed	-$6.78M	–	167
2021 Q1	$6.78M	Hold	50,000	–	–	0.13%	93
2020 Q4	$7.04M	Buy	+50,000	New	+$6.4M	0.13%	82
2020 Q1	–	Sell	-50,000	Closed	-$4.76M	–	117
2019 Q4	$4.76M	Buy	+50,000	New	+$4.32M	0.09%	70
2019 Q2	–	Sell	-50,000	Closed	-$4.53M	–	154
2019 Q1	$4.53M	Buy	+50,000	New	+$4.25M	0.09%	78

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PointState Capital's XBI Position: Q3 2022 in Review

PointState Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 309,004 shares — an estimated $22.9M sold.

PointState Capital first reported a position in XBI in Q1 2016 and held it in 7 quarters. The position peaked at $24.5M in Q3 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

PointState Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 309,004 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $22.9M.
PointState Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and held it in 7 quarters.
PointState Capital's State Street SPDR S&P Biotech ETF position peaked at $24.5M in Q3 2021.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.